Oncogene · 2019 · 32 citations · 48 references
MedicineCancer BiologyOncologyCell SignalingMolecular OncologyOncogenesCancer Cell SignalingCancer ProgressionOncogene MutationsOncogenic Signaling PathwaysReceptor Tyrosine Kinase OncogenesSignal Transduction In CancerCancer Signaling PathwaysExtracellular Signal-regulated Kinase PathwayMek InhibitionMek InhibitorsNon-small Cell Lung Cancer TherapyOncogenic TransformationRaf-mek-erk SignalingType Ii Kinase Inhibitors
Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAFP261A and CRAFP207S. To our knowledge, both mutations are novel in lung cancer and CRAFP261A has not been previously reported in cancer. Expression of CRAFP261A in HEK293T cells and BEAS-2B lung epithelial cells led to increased ERK pathway activation in a dimer-dependent manner, accompanied with loss of CRAF phosphorylation at the negative regulatory S259 residue. Moreover, stable expression of CRAFP261A in mouse embryonic fibroblasts and BEAS-2B cells led to anchorage-independent growth. Consistent with a previous report, we could not observe a gain-of-function with CRAFP207S. Type II but not type I RAF inhibitors suppressed the CRAFP261A-induced ERK pathway activity in BEAS-2B cells, and combinatorial treatment with type II RAF inhibitors and a MEK inhibitor led to a stronger ERK pathway inhibition and growth arrest. Our findings suggest that the acquisition of a CRAFP261A mutation can provide oncogenic properties to cells, and that such cells are sensitive to combined MEK and type II RAF inhibitors. CRAF mutations should be diagnostically and therapeutically explored in lung and perhaps other cancers.
48
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Paul Wan, Mathew J. Garnett, S. Mark Roe et al. · Cell · 2004 · 2.8K citations · Full text
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag et al. · Nature · 2010 · 1.8K citations · Full text
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou, Kyung Song, Ivana Yen et al. · Nature · 2010 · 1.6K citations
Medicine, Cancer Biology, Oncology +15